HbA1c and Thalassemia Trait: Can Your Diabetes Test Be Misleading? HPLC and CGM Guide
By Dr. Moxit Shah, DM Endocrinology
Vishuddha Diabetes, Thyroid, Weight Loss Clinic, Ahmedabad
Medical information reviewed: 17 November 2026 | Based on ADA Standards of Care in Diabetes—2026 and the October 2026 NGSP assay-interference review.
“My HbA1c says one thing, but my glucometer shows something else. Could thalassemia trait be affecting my diabetes report?” Sometimes, yes. An HbA1c test is a convenient way to assess average blood glucose over the previous two to three months. However, certain inherited haemoglobin conditions, including some thalassemias and haemoglobin variants, can make the result less reliable in particular circumstances.
Important: Not everyone with thalassemia trait has an inaccurate HbA1c. Many people with a carrier state can be monitored using an appropriate laboratory method. The result becomes a concern when the specific assay is affected, red-cell survival is altered, or HbA1c repeatedly disagrees with actual glucose measurements.
This guide explains HbA1c in thalassemia trait, the role of HPLC, when a falsely high or falsely low result may occur, and alternative tests such as fasting plasma glucose, CGM, glycated albumin and fructosamine.
What does HbA1c actually measure?
HbA1c—or glycated haemoglobin—is formed when glucose binds to haemoglobin in circulating red blood cells. Because these cells usually survive for approximately 120 days, HbA1c gives an estimate of glucose exposure over roughly the previous 2–3 months, with greater weight from more recent weeks.
For many people with diabetes, HbA1c is a valuable measure of overall management. But it is an indirect indicator: the test relies on both the laboratory’s ability to identify glycated haemoglobin correctly and the usual life span of red blood cells.
Read our related guide to understanding HbA1c results and targets.
What is thalassemia trait, and why is it relevant to diabetes testing?
Thalassemia refers to inherited conditions that affect the production of haemoglobin’s globin chains. A person with thalassemia trait (carrier status) may have small red blood cells (microcytosis), mild anaemia or no symptoms. More severe thalassemia syndromes may involve substantial anaemia, increased red-cell destruction or blood transfusions.
The effects on HbA1c are not identical across beta-thalassemia trait, alpha-thalassemia trait, more severe thalassemia, and associated haemoglobin variants such as HbE. They also vary between individuals.
For a patient in Ahmedabad, the practical lesson is simple: tell your endocrinologist if you have thalassemia trait, a known haemoglobin variant, an unusual haemoglobin electrophoresis report or a history of repeated blood transfusions. Do not assume that the HbA1c is automatically false—or automatically accurate.
How can thalassemia or a haemoglobin variant make HbA1c misleading?
There are two different mechanisms, and distinguishing them is essential.
1. Analytical interference: The laboratory method matters
Some HbA1c analysers may not separate or detect certain haemoglobin variants accurately. This can cause a falsely high, falsely low, unreportable or flagged result, depending on the specific variant and the exact assay platform used. A different validated method may give a more reliable answer.
The National Glycohemoglobin Standardization Program (NGSP) publishes method-specific interference tables, including information on HbS, HbC, HbE, HbD and elevated fetal haemoglobin. Laboratories can use these data to choose an appropriate assay. See the NGSP assay-interference table, updated October 2026.
2. Altered red-cell survival: Even an accurate assay can misrepresent glucose exposure
When red blood cells are destroyed or replaced more quickly than usual, they have less time to accumulate glycated haemoglobin. HbA1c may be falsely low relative to actual average glucose, regardless of which HbA1c method is used.
This problem may occur in clinically significant haemolysis, certain severe thalassemia syndromes, recent blood loss and other conditions that shorten red-cell survival. Recent transfusions can also complicate interpretation. Conversely, iron-deficiency anaemia is associated with higher-than-expected HbA1c in some circumstances.
Crucial distinction: An “HPLC HbA1c” report does not automatically correct a false result caused by a shortened red-cell life span. HPLC may help with some laboratory interferences, but it cannot restore normal red-cell biology.
Does beta-thalassemia trait always cause a falsely low HbA1c?
No. It would be inaccurate to claim that all beta-thalassemia carriers have falsely low HbA1c or that their diabetes must never be assessed with the test. Many carriers have sufficient red-cell survival and can obtain a clinically useful HbA1c when the assay is appropriate.
Concerns rise when the person also has significant anaemia or haemolysis, a coexisting haemoglobin variant, a flagged chromatogram, recent transfusions, or a marked mismatch between HbA1c and glucose readings.
Likewise, a “normal” HbA1c should not overrule repeated high laboratory glucose readings or convincing CGM evidence simply because a person has carrier status.
Is HPLC the best HbA1c test for thalassemia trait?
HPLC (high-performance liquid chromatography) is a common laboratory method for measuring HbA1c. Some ion-exchange HPLC systems produce a chromatogram that helps the laboratory recognise unusual peaks or possible variants. But different HPLC systems behave differently, and some variants may interfere with particular assays.
Other laboratory methods, including immunoassay, enzymatic methods, boronate-affinity chromatography and additional HPLC platforms, have their own strengths and limitations. No broad method label can guarantee accuracy in every haemoglobin disorder.
Ask the laboratory for the exact assay manufacturer and model, whether the result has a variant or interference flag, and whether the method is known to be appropriate for your identified haemoglobin variant. If the problem is shortened red-cell survival rather than analytical interference, an alternative HbA1c platform alone will not solve it.
Note: HPLC for haemoglobinopathy screening and HPLC for HbA1c measurement are different analytical applications; the presence of an HPLC report does not mean the same test answered both questions.
What are the warning signs that an HbA1c result may be inaccurate?
Your endocrinologist may question the result if:
- HbA1c and measured glucose disagree repeatedly: for example, HbA1c appears reassuring even though several reliable fasting, post-meal or CGM readings are high.
- The HbA1c result changes unexpectedly despite similar glucose records, especially following a change of laboratory or testing method.
- The laboratory report contains a variant warning, unusual peak, interference note or “result not reportable” message.
- You have significant anaemia, haemolysis, kidney disease, recent bleeding or a transfusion history that can change red-cell turnover.
- The HbA1c is biologically unusual for the patient’s clinical picture, especially at very low or extreme values.
Illustrative example, not an actual patient: Someone’s HbA1c is 5.8%, but glucose checks repeatedly show values near 180–220 mg/dL. These results deserve evaluation for inaccurate testing, red-cell conditions, sampling patterns and other explanations. A single discrepant number does not establish which explanation is correct.
Our existing article on high HbA1c with normal fasting blood sugar explains other reasons laboratory values can appear discordant.
How should diabetes be diagnosed when HbA1c is unreliable?
The ADA Standards of Care—2026 recommend using plasma glucose criteria, rather than HbA1c, when a condition makes the relationship between HbA1c and glycaemia unreliable. In nonpregnant adults, commonly used diagnostic thresholds include:
| Diagnostic test | Threshold indicating diabetes |
|---|---|
| Fasting plasma glucose | 126 mg/dL or higher after at least eight hours without caloric intake |
| 75-g OGTT (2-hour plasma glucose) | 200 mg/dL or higher at two hours |
| Random plasma glucose | 200 mg/dL or higher with classic symptoms of high glucose or a hyperglycaemic crisis |
In the absence of unmistakable hyperglycaemia, the diagnosis generally needs confirmatory testing. Your clinician should also investigate the reason the HbA1c may be unreliable.
CGM and finger-stick home readings are valuable monitoring tools, but they do not replace validated laboratory plasma-glucose tests for formal diabetes diagnosis.
If HbA1c cannot be trusted, how can diabetes control be monitored?
| Method | How it helps | Limitation |
|---|---|---|
| Finger-stick blood glucose (SMBG) | Shows glucose at fasting, before meals, after meals or when symptoms occur | May miss overnight or between-check fluctuations |
| Continuous glucose monitoring (CGM) | Shows glucose trends, time in range, high and low values; useful when HbA1c disagrees with glucose | Requires correct sensor use and interpretation; CGM-derived GMI is not identical to laboratory HbA1c |
| Glycated albumin | Can reflect recent glycaemia, often over about 2–3 weeks | Can be affected by abnormal albumin turnover or certain kidney or liver conditions |
| Fructosamine | Reflects glycated serum proteins over approximately 2–3 weeks | Protein concentration or turnover can influence the result; does not have identical clinical-outcome evidence to HbA1c |
| Laboratory fasting or post-load plasma glucose | Useful for diagnosing diabetes and confirming unexpected readings | One result does not show the full daily glucose pattern |
For many patients, a combination of SMBG or CGM, symptoms, and selected laboratory measures provides a safer assessment than relying on a single questionable HbA1c. Read our guide to HbA1c versus GMI on a CGM report and understanding Time in Range.
What tests might be considered when thalassemia trait is suspected?
The exact work-up depends on symptoms and prior reports. A clinician may assess complete blood count (CBC), red-cell indices, iron studies when indicated, haemoglobin electrophoresis or haemoglobinopathy HPLC, and other tests based on the suspected condition. Some inherited disorders require specialist interpretation or genetic evaluation.
This does not mean that every person with diabetes needs a thalassemia test. The investigation is appropriate when there is a relevant family history, persistent microcytosis, a previously identified carrier state, or a laboratory glucose–HbA1c mismatch that warrants explanation.
If iron deficiency is present, it should be managed for its own health implications and its potential effect on interpretation of HbA1c. Our related article explains how iron-deficiency anaemia may affect HbA1c.
Five practical steps if your HbA1c does not match glucose readings
- Do not change diabetes medicine based on one unexpected HbA1c. A false result can lead to unnecessary treatment intensification or missed hyperglycaemia.
- Bring both reports: HbA1c with the laboratory’s method information and recent reliable glucose or CGM records.
- Tell your doctor about known thalassemia trait, anaemia, transfusions or bleeding, and any previous haemoglobinopathy report.
- Ask whether laboratory plasma glucose testing or CGM review is needed while the discrepancy is investigated.
- Agree on a personalized follow-up strategy: use a suitable HbA1c assay if it is reliable, or use alternative glucose-monitoring approaches when it is not.
Frequently asked questions about thalassemia and HbA1c
Is HbA1c always low in thalassemia minor?
No. Many people with thalassemia trait have a clinically useful HbA1c. Results depend on the specific disorder, degree of anaemia or haemolysis, and the laboratory method.
Does an HbA1c test using HPLC eliminate all interference?
No. Some HPLC methods detect or flag variants, but results remain method dependent. Shortened red-cell survival can distort HbA1c regardless of the method used.
Can thalassemia make HbA1c falsely high as well as falsely low?
Yes, depending on the haemoglobin variant and the method, analytical interference can act in either direction. Conditions that shorten red-cell life generally bias HbA1c downward, whereas concurrent iron deficiency may raise it. The actual result needs clinical interpretation.
Can I be diagnosed with diabetes using fasting sugar instead of HbA1c?
Yes. If HbA1c is unreliable, ADA guidelines recommend plasma glucose-based diagnostic criteria, including fasting plasma glucose or a 75-g oral glucose tolerance test as appropriate.
Is thalassemia trait the same as thalassemia major?
No. Carrier states often cause mild or no symptoms, while severe syndromes may substantially affect red-cell survival and involve transfusions. The implications for HbA1c can differ greatly.
Can CGM replace HbA1c for monitoring diabetes?
When HbA1c is unreliable, CGM can provide valuable information about glucose trends, time in range and hypoglycaemia. It is not a substitute for laboratory plasma-glucose testing when formally diagnosing diabetes.
Is fructosamine better than HbA1c in every thalassemia patient?
No. Fructosamine or glycated albumin may be helpful when an accurate HbA1c cannot be obtained, but they have different time windows and their own limitations. The most suitable approach depends on the patient’s medical history.
Should I stop insulin if my HbA1c looks normal?
No. Do not stop or reduce insulin solely because an HbA1c appears normal, particularly if glucose readings are high or the result may be inaccurate. People with type 1 diabetes require ongoing insulin.
Diabetes and HbA1c interpretation in Ahmedabad
At Vishuddha Diabetes, Thyroid, Weight Loss Clinic, Dr. Moxit Shah, DM Endocrinology, provides individualized evaluation of diabetes laboratory results, glucose monitoring and treatment decisions. When HbA1c and glucose readings disagree, careful assessment can help prevent unnecessary medicine changes and missed poor glucose control.
Vishuddha Diabetes, Thyroid, Weight Loss Clinic
104–105, Elite Magnum, Bhuyangdev Cross Road, Opp. Utsav Elegance, Vardhmannagar Society, Ghatlodiya, Ahmedabad, Gujarat – 380061, India
Nearby areas: Memnagar and Naranpura
Dr. Moxit Shah, DM Endocrinology
Appointments: +91 99799 92797
Medical references
- American Diabetes Association: Diagnosis and Classification of Diabetes—Standards of Care in Diabetes 2026. Recommendations on discordant HbA1c and plasma-glucose diagnosis when haemoglobin variants or red-cell turnover are involved.
- National Glycohemoglobin Standardization Program: Factors That Interfere With HbA1c Test Results, updated October 2026. Method effects and red-cell lifespan considerations.
- NGSP: HbA1c Assay Interferences, updated October 2026. Method-specific variant-interference table.
- US National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): Haemoglobinopathies and Diabetes. Interpretation of variants and alternative glucose markers.
- ADA: Glycemic Goals, Hypoglycemia and Hyperglycemic Crises—Standards of Care in Diabetes 2026. Alternative monitoring when HbA1c interpretation is unreliable.
Medical disclaimer: This article is for general education, not a diagnosis or individualized prescription. The illustration’s numerical results are hypothetical, not an actual patient or a conversion rule. HbA1c interpretation depends on the precise haemoglobin condition, red-cell survival and laboratory method. Never change or stop diabetes medicines without advice from your treating clinician.
